276 related articles for article (PubMed ID: 24184344)
1. Dissolution methodology for taste masked oral dosage forms.
Gittings S; Turnbull N; Roberts CJ; Gershkovich P
J Control Release; 2014 Jan; 173():32-42. PubMed ID: 24184344
[TBL] [Abstract][Full Text] [Related]
2. Film coatings for taste masking and moisture protection.
Joshi S; Petereit HU
Int J Pharm; 2013 Dec; 457(2):395-406. PubMed ID: 24148666
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Dissolution Model Can Predict the in Vivo Taste Masking Performance of Coated Multiparticulates.
Keeley A; Teo M; Ali Z; Frost J; Ghimire M; Rajabi-Siahboomi A; Orlu M; Tuleu C
Mol Pharm; 2019 May; 16(5):2095-2105. PubMed ID: 30900905
[TBL] [Abstract][Full Text] [Related]
4. A review on the taste masking of bitter APIs: hot-melt extrusion (HME) evaluation.
Maniruzzaman M; Boateng JS; Chowdhry BZ; Snowden MJ; Douroumis D
Drug Dev Ind Pharm; 2014 Feb; 40(2):145-56. PubMed ID: 23763436
[TBL] [Abstract][Full Text] [Related]
5. Is rat a good model for assessment of particulate-based taste-masked formulations?
Ali J; Chiang M; Lee JB; Voronin GO; Bennett J; Cram A; Kagan L; Garnett MC; Roberts CJ; Gershkovich P
Eur J Pharm Biopharm; 2020 Jan; 146():1-9. PubMed ID: 31726218
[TBL] [Abstract][Full Text] [Related]
6. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
Otsuka K; Shono Y; Dressman J
J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
[TBL] [Abstract][Full Text] [Related]
7. Practical approaches of taste masking technologies in oral solid forms.
Douroumis D
Expert Opin Drug Deliv; 2007 Jul; 4(4):417-26. PubMed ID: 17683254
[TBL] [Abstract][Full Text] [Related]
8. Tannate complexes of antihistaminic drug: sustained release and taste masking approaches.
Rahman Z; Zidan AS; Berendt RT; Khan MA
Int J Pharm; 2012 Jan; 422(1-2):91-100. PubMed ID: 22037447
[TBL] [Abstract][Full Text] [Related]
9. Taste-masking assessment of solid oral dosage forms--a critical review.
Pein M; Preis M; Eckert C; Kiene FE
Int J Pharm; 2014 Apr; 465(1-2):239-54. PubMed ID: 24509066
[TBL] [Abstract][Full Text] [Related]
10. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms.
Arima H; Higashi T; Motoyama K
Ther Deliv; 2012 May; 3(5):633-44. PubMed ID: 22834407
[TBL] [Abstract][Full Text] [Related]
11. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
12. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
13. [Taste-masking possibilities in solid dosage forms].
Szakonyi G; Zelkó R
Acta Pharm Hung; 2012; 82(2):81-90. PubMed ID: 22870781
[TBL] [Abstract][Full Text] [Related]
14. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
15. Utilization of a modified special-cubic design and an electronic tongue for bitterness masking formulation optimization.
Li L; Naini V; Ahmed SU
J Pharm Sci; 2007 Oct; 96(10):2723-34. PubMed ID: 17506509
[TBL] [Abstract][Full Text] [Related]
16. Taste masking analysis in pharmaceutical formulation development using an electronic tongue.
Zheng JY; Keeney MP
Int J Pharm; 2006 Mar; 310(1-2):118-24. PubMed ID: 16431048
[TBL] [Abstract][Full Text] [Related]
17. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the solubility and masking the bitter taste of propiverine using crystalline complex formation.
Ogata T; Tanaka D; Ozeki T
Drug Dev Ind Pharm; 2014 Aug; 40(8):1084-91. PubMed ID: 23789589
[TBL] [Abstract][Full Text] [Related]
19. Taste-masking methods in multiparticulate dosage forms with a focus on poorly soluble drugs.
Simšič T; Planinšek O; Baumgartner A
Acta Pharm; 2024 Jun; 74(2):177-199. PubMed ID: 38815202
[TBL] [Abstract][Full Text] [Related]
20. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
